Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TaiGen Biotechnology will acquire the worldwide rights for nemonoxacin, a novel non-fluorinated quinolone antibiotic indicated for treatment of antibiotic-resistant infection, from Warner Chilcott.
Subscribe to our email newsletter
Following the transfer of rights, TaiGen will hold exclusive rights for development, manufacture, commercialization and sub-licensing of nemonoxacin.
TaiGen originally licensed nemonoxacin product rights in ten Asian countries and worldwide development rights through Phase II from Procter & Gamble Pharmaceuticals, which was acquired by Warner Chilcott in October 2009.
In August 2010, Warner Chilcott regained all rights outside the TaiGen territories after TaiGen announced positive data for the drug candidate.
Nemonoxacin demonstrated effective eradication of MRSA and quinolone-resistant MRSA in two Phase II trials for community acquired pneumonia (CAP) and diabetic foot infection.